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Abstract
Prospective studies of the potential health consequences of trade and investment treaties, such as the Trans-Pacific 
Partnership, are critical. These studies can make visible to trade policy-makers the potential negative impacts 
associated to such treaties and can influence the outcomes of such negotiations. However, few researchers have 
examined retrospectively the consequences of trade agreements. With more than 400 trade agreements and more 
than 2000 investment treaties currently in force, researchers have a large corpus of agreements to analyse in order 
to assess not only their potential impacts on health system and population health, but also their actual impacts. 
This comment suggests some research questions that would benefit from retrospective inquiry.
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In the last 20 years, the consequences of trade and investment treaties for population health and for health systems have received an increasing level of attention in 
the scholarly and policy literature. These publications have 
examined what could be the consequences of the World Trade 
Organisation’s (WTO’s) agreements, of regional agreements 
and plurilateral agreements for population health and/or for 
health systems. In their article “The Trans-Pacific Partnership: 
is it everything we feared for health?,” Labonté and colleagues1 
further contribute to this literature with a rigorous analysis of 
how this new agreement could affect health in the future.
These prospective analyses are critical to ensure that the 
potential health consequences of trade policy are taken into 
considerations by trade policy-makers (see Friel et al,2 for a 
narrative review of this literature). At the national level, where 
trade policy objectives are first set, health considerations are 
often absent or ignored by decision-makers. National trade 
policy’s objectives are mostly defined by the interplay of 
the economic interests at stake. The influence of economic 
actors wishing to expand or consolidate export markets or 
their investments abroad vs. the influence the economic actors 
advocating to keep protectionist measures in place to ensure 
domestic production or competitiveness are still the main 
factors to understand the content of national trade policy.
Analytical work which highlight the health risks associated 
to trade and investment agreements can support the national 
health agencies involved in inter-sectoral work to influence 
their trade colleagues. It can also inform the work of health 
professionals, their associations and various organisations 
advocating for health-promoting public policies at the 
national and global level. Such prospective analysis can clarify 
unintended consequences of the provisions of the agreements, 
it can shed light on the costs and risks that were not integrated 
into the trade negotiators calculation of the “trade-offs” at 
stake. 
Trade negotiations are still viewed by negotiators as mutual 
exchanges of concessions (“you open your agricultural 
markets for my producers, in exchange I will open my 
telecommunications markets to your providers”). If the costs 
in terms of higher prices for medicines, or reduced capacity to 
regulate to protect and promote health are not made visible, 
they will not even be part of the “grand bargain” of trade 
negotiations. Making these costs visible is a necessary, if not 
sufficient, step toward tackling the political determinants of 
health (see Ottersen et al3).
However, one type of research is not sufficiently conducted. 
Few have examined retrospectively the impact of trade 
agreements. With more than 400 trade agreements and more 
than 2000 investment treaties currently in force, researchers 
now have a large corpus of agreements to analyse in order to 
assess not only their potential impacts on health system and 
population health, but also their actual impacts. 
To my knowledge, this type of retrospective inquiry has been 
limited to three areas:
1)	 The impact of greater economic integration, which is 
partially linked to trade agreements, on income and 
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poverty as key determinants of health (see a review of 
that literature in Blouin et al4);
2)	 The impact of intellectual property provisions in trade 
agreements on the price of medicines,5,6 and
3)	 The legal consequences of trade disputes that have 
involved human health issues (see for example McGrady7).
Several other empirical questions could be explored with 
retrospective studies. Let’s take the example of the risk of 
regulatory chill. It refers to situations where “governments 
become more reluctant to enact new policy for fear of being 
sued.”1 This is a real concern from a population health 
perspective, as it could mean that the most effective or 
promising measures are avoided because officials do not want 
to take a risk that this measure be challenged in a trade or 
investment disputes. This concern is especially salient in the 
case of investor-statement dispute settlement, where private 
organisations can directly challenge policies that they deemed 
to violate trade and investments treaties.
To what extent policy-makers in national agencies have 
decided against, or modified certain policy and regulations 
because they feared that it would lead to trade disputes? 
To what extent local and national authorities integrate an 
analysis of the exposure risks? Even when policy-makers are 
made aware of a potential risk, ie, that a measure could be 
challenged by foreign investors, how much this information 
influence their decision-making? Can we identify political or 
economic conditions that are more likely to lead to regulatory 
chill in health policy-making?
Another question relates to the broader policy-making 
context. Are trade agreements being used by private industry 
or other opponents of public health measures as a political 
resource to block or modify legislation or regulation? Many 
health-promoting public policies under consideration by 
national and local governments have been opposed by private 
industry using traditional domestic lobbying and advocacy 
strategy. The numerous failed attempts by state legislatures 
to impose taxes on sweetened beverages in the United States 
illustrate the influence of such opposition.8 To what extent 
trade and investment treaties are seen and used as a resources 
by industry to oppose a specific policy? Do traditional 
advocacy and lobbying tools remain the main channels for 
influence?
Answering these types of question will require for political 
scientists and other social scientists to undertake in-depth 
case studies and to use qualitative research methods such as 
process tracing which allows to examine the policy process 
with a view to understand the causal sequences leading to 
particular policy decisions.9
On the other hand, other retrospective inquiries will 
require quantitative methods, in order to ascertain whether 
trade agreements have had positive or negative impacts on 
the various determinants of health. For example, has the 
liberalisation of agricultural trade improve or worsen food 
security? Facilated or created obstacles to the adoption of 
healthier diets? Similar questions can be asked about the 
impact of trade agreements on national health systems. For 
instance, has the liberalisation of trade in services led to 
increased privatisation of health services and insurance? Or 
led to other transformations in the provision and financing of 
healthcare services? In sum, a diversity of research methods 
and disciplinary expertise will be require to investigate the 
multiple linkages between trade and health.
A retrospective research program of the impact of trade and 
investment treaties on national and sub-national policy-
making would complement the existing work on the potential 
risks and benefits of such treaties. Such research program can 
help identify the priority areas to focus on to ensure that trade 
and investment treaties contribute to improve population 
health, and rather than increasing the price of essential 
medicines, reducing access to services, or reducing policy 
space for health-promoting public policies.
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